Belite Bio Seeks Tinlarebant Approval in Singapore, UK and Switzerland
Belite Bio filed marketing applications for tinlarebant to treat Stargardt disease type 1 in Singapore, the UK and Switzerland through Access Consortium. If authorized, tinlarebant would be the first approved treatment for the disease in those markets. U.S. and Japanese applications have been accepted for accelerated r